Non-invasive SARS-CoV-2 RNA detection and human transcriptome analysis using skin surface lipids.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 10 2024
Historique:
received: 14 06 2024
accepted: 25 10 2024
medline: 30 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: epublish

Résumé

There have been several reports of skin manifestations in patients with coronavirus disease 2019 (COVID-19). However, it is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be detected on the skin surface, including the sebum, of these patients. In this study, SARS-CoV-2 RNA was detected using real-time reverse-transcription polymerase chain reaction (RT-PCR) assay of skin surface lipids (SSLs) collected using an oil-blotting film from the faces of hospitalized patients with COVID-19. Human transcriptome analysis was also performed using the same samples. In facial SSLs of patients with COVID-19, the RT-PCR positivity rate was 84.6% (11/13 samples) within 5 days and 30.4% (7/23 samples) by 6-10 days of symptom onset. In the transcriptome analysis, the most characteristic SSL-RNA profile was the upregulation of interferon-stimulated gene (ISG)-related genes, such as ISG15, IFITM1, and MX1. This study presents an alternative technique using SSLs for non-invasive SARS-CoV-2 RNA detection and simultaneous analysis of human molecular pathogenesis in patients with COVID-19.

Identifiants

pubmed: 39472469
doi: 10.1038/s41598-024-77862-0
pii: 10.1038/s41598-024-77862-0
doi:

Substances chimiques

RNA, Viral 0
Lipids 0
ISG15 protein, human 60267-61-0
Ubiquitins 0
Myxovirus Resistance Proteins 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26057

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP21fk0108104

Informations de copyright

© 2024. The Author(s).

Références

Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 323, 1843–1844 (2020).
pubmed: 32159775
Peng, L. et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. J. Med. Virol. 92, 1676–1680 (2020).
doi: 10.1002/jmv.25936 pubmed: 32330305 pmcid: 7264521
Wyllie, A. L. et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl. J. Med. 383, 1283–1286 (2020).
doi: 10.1056/NEJMc2016359 pubmed: 32857487
Matic, N. et al. Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection. Eur. J. Clin. Microbiol. Infect. Dis. 40, 447–450 (2021).
doi: 10.1007/s10096-020-04090-5 pubmed: 33236269
Polly, S. & Fernandez, A. P. Common skin signs of COVID-19 in adults: An update. Cleve Clin. J. Med. 89, 161–167 (2022).
doi: 10.3949/ccjm.89a.21126 pubmed: 35232829
Majumdar, R. et al. SARS-CoV-2 RNA detection in formalin-fixed paraffin-embedded (FFPE) tissue by droplet digital PCR (ddPCR). Clin. Chim. Acta 532, 181–187 (2022).
doi: 10.1016/j.cca.2022.05.007 pubmed: 35550815
Marzano, A. V. et al. SARS-CoV-2 detection by digital polymerase chain reaction and immunohistochemistry in skin biopsies from 52 patients with different COVID-19-associated cutaneous phenotypes. Dermatology. 239, 584–591 (2023).
doi: 10.1159/000530746 pubmed: 37075721
Fathizadeh, H. et al. Study presence of COVID-19 (SARS-CoV-2) in the sweat of patients infected with COVID-19. Microb. Pathog 149, 104556 (2020).
doi: 10.1016/j.micpath.2020.104556 pubmed: 33031898 pmcid: 7534876
Arslan, B., Bercin, S., Aydogan, S., Islamoglu, Y. & Dinc, B. SARS-CoV-2 is not found in the sweat of COVID-19 positive patients. Ir. J. Med. Sci. 191, 27–29 (2022).
doi: 10.1007/s11845-021-02537-y pubmed: 33580478
Recalcati, S., Tonolo, S., Meroni, E. & Fantini, F. SARS-CoV-2 in the sweat of COVID-19-positive patients: A possible route of transmission? J. Eur. Acad. Dermatol. Venereol. 35, e865–e866 (2021).
doi: 10.1111/jdv.17607 pubmed: 34416062 pmcid: 8656368
Inoue, T. et al. Non-invasive human skin transcriptome analysis using mRNA in skin surface lipids. Commun. Biol. 5, 215 (2022).
doi: 10.1038/s42003-022-03154-w pubmed: 35264722 pmcid: 8907185
Shima, K. et al. Non-invasive transcriptomic analysis using mRNAs in skin surface lipids obtained from children with mild-to-moderate atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 36, 1477–1485 (2022).
doi: 10.1111/jdv.18173 pubmed: 35462437 pmcid: 9545805
Yamamoto-Hanada, K. et al. mRNAs in skin surface lipids unveiled atopic dermatitis at 1 month. J. Eur. Acad. Dermatol. Venereol. 37, 1385–1395 (2023).
doi: 10.1111/jdv.19017 pubmed: 36897437
Uehara, Y. et al. Non-invasive diagnostic tool for Parkinson’s disease by sebum RNA profile with machine learning. Sci. Rep. 11, 18550 (2021).
doi: 10.1038/s41598-021-98423-9 pubmed: 34545158 pmcid: 8452747
Song, M., Bai, H., Zhang, P., Zhou, X. & Ying, B. Promising applications of human-derived saliva biomarker testing in clinical diagnostics. Int. J. Oral Sci. 15, 2 (2023).
doi: 10.1038/s41368-022-00209-w pubmed: 36596771 pmcid: 9810734
Frediani, J. K. et al. The new normal: Delayed peak SARS-CoV-2 viral loads relative to symptom onset and implications for COVID-19 testing programs. Clin. Infect. Dis. 78, 301–307 (2024).
doi: 10.1093/cid/ciad582 pubmed: 37768707
Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. 21, 147–161 (2023).
pubmed: 36460930
Sarkar, L., Liu, G. & Gack, M. U. ISG15: Its roles in SARS-CoV-2 and other viral infections. Trends Microbiol. 31, 1262–1275 (2023).
doi: 10.1016/j.tim.2023.07.006 pubmed: 37573184
Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020).
doi: 10.1126/science.abc6027 pubmed: 32661059 pmcid: 7402632
Domizio, J. D. et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 603, 145–151 (2022).
doi: 10.1038/s41586-022-04421-w pubmed: 35045565 pmcid: 8891013
Ohue-Kitano, R. et al. Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84. JCI Insight. 8, e165469 (2023).
doi: 10.1172/jci.insight.165469 pubmed: 36480287 pmcid: 9977302
Greenberg, E. et al. (ed, N.) Circadian control of interferon-sensitive gene expression in murine skin. Proc. Natl. Acad. Sci. U S A 117 5761–5771 (2020).
doi: 10.1073/pnas.1915773117 pubmed: 32132203 pmcid: 7084068
Shirato, K. et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn J. Infect. Dis. 73, 304–307 (2020).
doi: 10.7883/yoken.JJID.2020.061 pubmed: 32074516
Itokawa, K., Sekizuka, T., Hashino, M., Tanaka, R. & Kuroda, M. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS One 15, e0239403 (2020).
doi: 10.1371/journal.pone.0239403 pubmed: 32946527 pmcid: 7500614
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
doi: 10.1186/s13059-014-0550-8 pubmed: 25516281 pmcid: 4302049
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
doi: 10.1093/nar/28.1.27 pubmed: 10592173 pmcid: 102409
Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
doi: 10.1038/nprot.2008.211 pubmed: 19131956
Sherman, B. T. et al. A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216–W221 (2022).
doi: 10.1093/nar/gkac194 pubmed: 35325185 pmcid: 9252805

Auteurs

Tetsuya Kuwano (T)

Biological Science Research, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga-gun, 321- 3497, Tochigi, Japan. kuwano.tetsuya@kao.com.

Takayuki Kanno (T)

Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, 162-8640, Tokyo, Japan.

Minoru Tobiume (M)

Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, 162-8640, Tokyo, Japan.

Yuichiro Hirata (Y)

Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, 162-8640, Tokyo, Japan.

Harutaka Katano (H)

Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, 162-8640, Tokyo, Japan.

Michiko Koga (M)

Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo, Japan.
Department of Infectious Diseases and Applied Immunology, Hospital of Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Hiroyuki Nagai (H)

Department of Infectious Diseases and Applied Immunology, Hospital of Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Takeya Tsutsumi (T)

Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo, Japan.
Department of Infectious Diseases and Applied Immunology, Hospital of Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Noritada Yoshikawa (N)

Department of Allergy and Rheumatology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Hiroshi Yotsuyanagi (H)

Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo, Japan.
Department of Infectious Diseases and Applied Immunology, Hospital of Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Satoshi Kutsuna (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Department of Infection Control and Prevention, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.

Yusuke Miyazato (Y)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Department of Internal Medicine, Hashimoto Municipal Hospital, Wakayama, Japan.

Noriko Kinoshita-Iwamoto (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Norio Ohmagari (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Taiichiro Kobayashi (T)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Kazuaki Fukushima (K)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Masaru Tanaka (M)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Akifumi Imamura (A)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Yui Ueda (Y)

Biological Science Research, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga-gun, 321- 3497, Tochigi, Japan.

Maeko Iwamura (M)

Biological Science Research, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga-gun, 321- 3497, Tochigi, Japan.

Naoto Takada (N)

Biological Science Research, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga-gun, 321- 3497, Tochigi, Japan.

Takayoshi Inoue (T)

Biological Science Research, Kao Corporation, 2606 Akabane, Ichikai-machi, Haga-gun, 321- 3497, Tochigi, Japan.

Tetsuro Matano (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Department of AIDS Vaccine Development, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Ai Kawana-Tachikawa (A)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Department of AIDS Vaccine Development, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Tadaki Suzuki (T)

Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, 162-8640, Tokyo, Japan. tksuzuki@niid.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH